Cargando…

Elevated levels of mitochondrial CoQ(10) induce ROS-mediated apoptosis in pancreatic cancer

Reactive oxygen species (ROS) are implicated in triggering cell signalling events and pathways to promote and maintain tumorigenicity. Chemotherapy and radiation can induce ROS to elicit cell death allows for targeting ROS pathways for effective anti-cancer therapeutics. Coenzyme Q(10) is a critical...

Descripción completa

Detalles Bibliográficos
Autores principales: Dadali, Tulin, Diers, Anne R., Kazerounian, Shiva, Muthuswamy, Senthil K., Awate, Pallavi, Ng, Ryan, Mogre, Saie, Spencer, Carrie, Krumova, Katerina, Rockwell, Hannah E., McDaniel, Justice, Chen, Emily Y., Gao, Fei, Diedrich, Karl T., Vemulapalli, Vijetha, Rodrigues, Leonardo O., Akmaev, Viatcheslav R., Thapa, Khampaseuth, Hidalgo, Manuel, Bose, Arindam, Vishnudas, Vivek K., Moser, A. James, Granger, Elder, Kiebish, Michael A., Gesta, Stephane, Narain, Niven R., Sarangarajan, Rangaprasad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952582/
https://www.ncbi.nlm.nih.gov/pubmed/33707480
http://dx.doi.org/10.1038/s41598-021-84852-z
Descripción
Sumario:Reactive oxygen species (ROS) are implicated in triggering cell signalling events and pathways to promote and maintain tumorigenicity. Chemotherapy and radiation can induce ROS to elicit cell death allows for targeting ROS pathways for effective anti-cancer therapeutics. Coenzyme Q(10) is a critical cofactor in the electron transport chain with complex biological functions that extend beyond mitochondrial respiration. This study demonstrates that delivery of oxidized Coenzyme Q(10) (ubidecarenone) to increase mitochondrial Q-pool is associated with an increase in ROS generation, effectuating anti-cancer effects in a pancreatic cancer model. Consequent activation of cell death was observed in vitro in pancreatic cancer cells, and both human patient-derived organoids and tumour xenografts. The study is a first to demonstrate the effectiveness of oxidized ubidecarenone in targeting mitochondrial function resulting in an anti-cancer effect. Furthermore, these findings support the clinical development of proprietary formulation, BPM31510, for treatment of cancers with high ROS burden with potential sensitivity to ubidecarenone.